Harrow Health announces CMS approval for reimbursement status for Iheezo 3%

Harrow announced that the Centers for Medicare & Medicaid Services, or CMS, has approved transitional pass-through reimbursement status for Iheezo 3%, which is indicated for ocular surface anesthesia. Beginning April 1 and for the three years thereafter, Iheezo will be eligible for separate reimbursement outside of the surgical bundled payment in both the Ambulatory Surgery Center, or ASC, and Hospital Outpatient Department, or HOPD, settings of care. CMS previously approved the issuance of a permanent, product-specific J-Code, enabling access to Iheezo for ophthalmologists, optometrists, and retina specialists for the in-office setting of care. This new CMS pass-through approval makes Iheezo the only ocular anesthetic with separate reimbursement in all traditional settings of care – the eyecare professional’s office, the ASC, and the HOPD.